Biotech | August 10, 2021
Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
A veteran in cell therapy and oncology commercialisation
A veteran in cell therapy and oncology commercialisation
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Nearly 6,000 patients have been treated with the drug since 2017
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
It is designed to tackle mental health issues
Drug formulations and biologics make impressive gains
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
Subscribe To Our Newsletter & Stay Updated
